An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
Condition(s):Lennox Gastaut SyndromeLast Updated:May 6, 2023Available
Hide Studies Not Open or Pending
Condition(s):Lennox Gastaut SyndromeLast Updated:May 6, 2023Available
Condition(s):Lennox Gastaut Syndrome; Dravet SyndromeLast Updated:March 20, 2024Not yet recruiting
Condition(s):Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable; Seizures; Seizures, GeneralizedLast Updated:February 12, 2024Recruiting
Condition(s):Lennox-Gastaut SyndromeLast Updated:September 1, 2022Withdrawn
Condition(s):Lennox-Gastaut SyndromeLast Updated:March 11, 2019Completed
Condition(s):EpilepsyLast Updated:October 30, 2020Terminated
Condition(s):Dravet Syndrome; Lennox Gastaut SyndromeLast Updated:December 16, 2021Withdrawn
Condition(s):Epilepsy; Lennox-Gastaut Syndrome, IntractableLast Updated:June 7, 2023Recruiting
Condition(s):Epilepsy; Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS)Last Updated:February 21, 2024Active, not recruiting
Condition(s):Seizures; EpilepsyLast Updated:April 27, 2010Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.